Drug Combination Details
| General Information of the Combination (ID: C51783) | |||||
|---|---|---|---|---|---|
| Name | Rottlerin NP Info | + | TNF-related apoptosis inducing ligand Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Brain cancer
[ICD-11: 2A00]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Down-regulation | Expression | BIRC5 | Molecule Info |
Pathway MAP
|
|
| Down-regulation | Expression | XIAP | Molecule Info |
Pathway MAP
|
||
| In-vitro Model | U-87MG ATCC | CVCL_0022 | Glioblastoma | Homo sapiens | ||
| A-172 | CVCL_0131 | Glioblastoma | Homo sapiens | |||
| T98 | CVCL_B368 | Glioblastoma | Homo sapiens | |||
| U-251MG | CVCL_0021 | Astrocytoma | Homo sapiens | |||
| Experimental
Result(s) |
Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Rottlerin sensitizes glioma cells to TRAIL-induced apoptosis by inhibition of Cdc2 and the subsequent downregulation of survivin and XIAP. Oncogene. 2005 Jan 27;24(5):838-49. | |||
